Sunshine Biopharma, Inc.
SBFMHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframeSunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and. At a $2.2M market cap, Sunshine Biopharma, Inc. ranks as a micro-cap company within healthcare. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer.
Market Cap
$2.2M
Beta
1.35
P/E (TTM)
—
P/E (Fwd)
0.00
EPS (TTM)
$-161.84
EPS (Fwd)
$199.80
ROE
-21.9%
ROA
-9.9%
Cash
$14.0M
Total Debt
$678,338
Free CF
-$2.0M
52W Change
-99.2%
Annual Financials
Cash vs Debt
Where SBFM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SBFM finished 94.01% below its 150-day moving average ($4.01) and 96.02% below its 200-day moving average ($6.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SBFM overbought or oversold?
At the October 20, 2026 close, SBFM's RSI(14) was 27.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $14.0M in cash comfortably exceeding the $678K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$2.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -21.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $4.3M (2022) to $36.3M (2025), reflecting a 735% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sunshine Biopharma, Inc.'s trajectory.